XRAY enters the back half of August down 21% in a month, with a cluster of director buys in June now sitting underwater and options traders showing their most defensive posture in weeks.
The most striking data point is not the short interest level — it's what the board did when the stock cracked through $10. Six directors purchased shares in June, collectively spending roughly $617,000 between June 11 and June 15 at prices ranging from $9.88 to $10.14. A seventh director, Chairman Greg Lucier, bought 15,000 shares at $12.45 back in March. The net insider figure over the trailing 90 days comes to a positive 66,643 shares, worth just under $669,000. That's a meaningful signal of conviction — and yet the stock closed Tuesday at $11.11, leaving many of those June purchases barely in the money after last week's post-earnings slide.
The earnings print tells you why shorts stayed in the name. The August 6 report sent XRAY down 12% in a single session and a further 16% over the following five days — one of the sharpest post-result moves in the stock's recent history. Short interest, already elevated at roughly 14.4% of the float heading into the print, dropped materially in the aftermath: it fell from around 28.7 million shares on August 10 to 24.0 million shares by August 18, a decline of about 16% in a week. That's not a capitulation by bears — it looks more like profit-taking after a well-timed trade. At 12% of the float, the short position remains high relative to most health-care peers. Critically, the borrow market stays loose. Availability runs at 519%, meaning there are more than five shares available to lend for every one currently borrowed. Cost to borrow is a negligible 0.47%. Bears face no squeeze pressure of any kind.
Options positioning has shifted noticeably more defensive since the earnings sell-off. The put/call ratio has climbed to 0.75, roughly 1.6 standard deviations above its 20-day average of 0.63 — the most protective skew in several weeks, though well short of the 52-week high of 1.21. The pattern is consistent: the PCR ran below 0.55 through most of July, before jumping sharply after August 6. Options traders who were relaxed into earnings are now hedging the rubble.
The Street reflects the same ambivalence. Piper Sandler raised its target to $14 in late July — before the earnings disaster — keeping a Neutral rating. BMO Capital initiated at $12 in early July with a Market Perform. Barclays carries an Underweight with a $9 target, cut from $12 in June. UBS holds a Buy but trimmed to $17 from $18 in May. The consensus mean target of roughly $13.60 implies about 22% upside from current levels, but that figure was compiled before the stock fell another 16% post-earnings, so the effective implied return is likely higher — and arguably reflects a Street that hasn't fully re-anchored. The bull case rests on restructuring progress and forward EPS recovery. The bear case centres on executive instability, still-negative sales growth, and a profitability outlook that deteriorated again this quarter. Valuation multiples have compressed sharply: the price-to-book has fallen by around 0.32 over the past month to 1.59, and the trailing P/E has compressed nearly two full turns over the same period to 7.6x.
Institutional flows add one more layer. BlackRock added 7.5 million shares as of July 31, bringing its position to 13.4% of shares outstanding — a meaningful accumulation. State Street added 2 million shares over the same period. Jupiter Fund Management added 3.7 million shares through June. These are not small top-ups. Against that, Cooke & Bieler trimmed 873,000 shares and Marshall Wace cut 708,000 — the latter a natural tell for a long/short fund reducing a long. The picture is one of passive and value-oriented buyers absorbing shares while some active managers take chips off the table.
The next scheduled catalyst is the November 5 earnings release. Between now and then, what matters is whether Dentsply Sirona can demonstrate any sequential revenue stabilisation — the board's collective bet with their own capital — or whether the structural headwinds that drove a 12% post-earnings drop recur for a fourth consecutive quarter.
See the live data behind this article on ORTEX.
Open XRAY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
